Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Otsuka Busulfex's Overall Survival Claim Does Not Survive CDER Advertising Scrutiny

This article was originally published in The Pink Sheet Daily

Executive Summary

Statistical analyses based on pivotal trial data and used to promote a drug must prove what they purport to prove, FDA's Office of Prescription Drug Promotion says in an NOV letter to Otsuka over a website for the leukemia drug Busulfex (busulfan).
Advertisement

Related Content

FDA Turns Off Otsuka’s Abilify Dimmer Switch Graphic
FDA Cites Gleevec For Promoting Unapproved Indications Three Weeks Before Expanding Label
DDMAC Slamming The Door On Open-Label Studies In Promotions
FDA Cancer Endpoint Guidance Abandons Placebos, Moves Beyond Survival
FDA Cancer Endpoint Guidance Abandons Placebos, Moves Beyond Survival

Topics

Advertisement
UsernamePublicRestriction

Register

PS073015

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel